Barclays Reinstates Medtronic Coverage, Cites Strong Growth in Heart Rhythm Devices
Barclays has resumed coverage of Medtronic with an Overweight rating and a $116 price target, pointing to robust expansion in the company’s electrophysiology business led by cardiac ablation systems for atrial fibrillation. The broker projects 60% to 70% growth in the EP segment, sees Affera and renal denervation as multi-year drivers, and expects …